Why Summit Therapeutics Inc. (SMMT) stock moved
Summit Therapeutics Inc. (SMMT) shares climbed 6.5% to $14.87 as of August 11, 2026, a significant gain from the prior close of $13.96. BestStocks flagged the session as a major change for SMMT. The move is tied to price move up. Below, we break down what changed for SMMT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
SMMT climbed 6.5% to $14.87
SMMT climbed 6.5% in its latest session, moving from $13.96 to $14.87.
What it means for Summit Therapeutics Inc. investors
For Summit Therapeutics Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Strong 6.5% price move on light volume. Weighing against that: Summit Therapeutics Inc. moved -10.08% intraday from $14.98 to $13.47; Summit Therapeutics Inc. (SMMT) moved -2.90% from $15.18 to $14.74 on 2026-07-22. Wall Street's consensus price target sits at $26.00, implying +74.8% upside from $14.87. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality low (56/100). With earnings roughly 69 days out, the next report is the most likely near-term test of the move.
SMMT price reaction
SMMT last traded at $14.87, up $0.91 (+6.52%) from the previous close of $13.96. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $12.55 and $15.47, and it currently sits about 79% of the way up that band.
Bullish and bearish analyst opinions on Summit Therapeutics Inc. (SMMT)
The consensus analyst price target on Summit Therapeutics Inc. (SMMT) is $26.00, 74.8% above the recent $14.87. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 1 downgrade. Here is how the bullish and bearish cases on SMMT line up.
The bullish case
- Wall Street's consensus price target of $26.00 implies +74.8% upside from $14.87.
- The Street's most bullish target is $38.00 (+155.5%).
- Material positive event.
- Strong 6.5% price move on light volume.
- Summit Therapeutics Inc. (SMMT) moved +8.37% from $13.50 to $14.63 on 2026-07-21.
The bearish case
- 1 analyst downgrade in the past 90 days, most recently HC Wainwright & Co. to Neutral (2026-05-22).
- Summit Therapeutics Inc. moved -10.08% intraday from $14.98 to $13.47.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 11, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for SMMT
Frequently asked questions about SMMT
Why did Summit Therapeutics Inc. (SMMT) stock move?
SMMT climbed 6.5% to $14.87. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did SMMT stock rise?
SMMT gained 6.52% ($0.91) versus the prior close of $13.96, last trading at $14.87 on 0.7× average volume.
When is Summit Therapeutics Inc.'s next earnings date?
SMMT's next earnings report is estimated for 2026-10-19 — about 69 days away.
What is the analyst price target for SMMT?
The consensus analyst price target for SMMT is $26.00, about 74.8% above the current $14.87. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 1 downgrade.
How BestStocks tracks SMMT
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for SMMT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 11, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.